New tests launched in February


New Tests

In February 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The new tests that launched in February 2022 by Mayo Clinic Laboratories:

THCCR | Carboxy-Tetrahydrocannabinol (THC-COOH) Confirmation and Creatinine Ratio, Random, Urine

This test is intended for measuring the carboxy-tetrahydrocannabinol to creatinine ratio to detect use of tetrahydrocannabinol.

THCCU | Carboxy-Tetrahydrocannabinol Confirmation and Creatinine Ratio, Random, Urine

This test is intended for measuring the carboxy-tetrahydrocannabinol to creatinine ratio as a part of a profile.

POWV | Powassan Virus, IgM, Enzyme-Linked Immunosorbent Assay, Serum

This test is intended for diagnosis of Powassan virus infection.

This test should not be used as a screening procedure for the general population.

This test should not be used as a "test of cure."

RPRT2 | Rapid Plasma Reagin Titer, Serum

This test is intended for determining the current disease status.

Monitoring response to therapy for syphilis.

This test cannot be used for testing spinal fluid specimens.

RPRT1 | Rapid Plasma Reagin (RPR) Screen with Reflex to Titer, Serum

This test is intended for determining the current disease status.

Monitoring response to therapy for syphilis.

Aid to diagnose congenital syphilis.

This test cannot be used for testing spinal fluid specimens.

This test is not intended for medical-legal use.

MHRP | Metamycoplasma hominis, Molecular Detection, PCR, Varies

This test is intended for rapid, sensitive, and specific identification of Metamycoplasma hominis from synovial fluid, genitourinary, reproductive, lower respiratory sources, pleural/chest fluid, pericardial fluid, and wound specimens.

This test is not intended for medicolegal use.

MHPRP | Metamycoplasma hominis, Molecular Detection, PCR, Plasma

This test is intended for rapid, sensitive, and specific identification of Metamycoplasma hominis from plasma.

This test is not intended for medicolegal use.

MHBRP | Metamycoplasma hominis, Molecular Detection, PCR, Blood

This test is intended for rapid, sensitive, and specific identification of Metamycoplasma hominis from whole blood.

PCPDS | Plasma Cell Proliferative Disorder, High Risk with Reflex Probes, Diagnostic FISH Evaluation, Bone Marrow

This test is intended for aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders using bone marrow specimens.

Identifying prognostic markers based on the abnormalities found.

This test should not be used to track the progression of disease.

ESBLS | Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacteria Surveillance Culture, Feces

This test is intended for screening for colonization of extended-spectrum beta-lactamase (ESBL)-producing organisms in stool.

Screening fecal microbiota transplant donor feces for ESBL-producing organisms.

This test is not intended for medicolegal use.

SPPS | Stiff-Person Spectrum Disorders Evaluation, including Progressive Encephalomyelitis with Rigidity and Myoclonus, Serum

This test is intended for evaluating patients with suspected stiff-person syndrome (classical or focal forms, such as stiff-limb or stiff-trunk) and progressive encephalomyelitis with rigidity and myoclonus using serum specimens.

SPPC | Stiff-Person Spectrum Disorders Evaluation, including Progressive Encephalomyelitis with Rigidity and Myoclonus, Spinal Fluid

This test is intended for evaluating patients with suspected stiff-person syndrome (classical or focal forms, such as stiff-limb or stiff-trunk) and progressive encephalomyelitis with rigidity and myoclonus using spinal fluid specimens.

SPPCI | Stiff-Person Spectrum Disorders including Progressive Encephalomyelitis with Rigidity and Myoclonus, Interpretation, Spinal Fluid

This test in intended for interpretation for the evaluation of stiff-person spectrum disorders including the classical or focal forms, such as stiff-limb or stiff-trunk, and progressive encephalomyelitis with rigidity and myoclonus using spinal fluid specimens.

SPPSI | Stiff-Person Spectrum Disorders, including Progressive Encephalomyelitis with Rigidity and Myoclonus, Interpretation, Serum

This test is intended for interpretation for the evaluation of stiff-person spectrum disorders including the classical or focal forms, such as stiff-limb or stiff-trunk, and progressive encephalomyelitis with rigidity and myoclonus using serum specimens.

In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:

Chantell Canfield

Chantell Canfield is a web content coordinator for Mayo Clinic Laboratories. She began working for Mayo Clinic in 2021.